Drugs / CT1190B
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07470073 | Apr 2026 → Dec 2027 expected | B-cell acute lymphoblastic leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07053670 | Jul → Dec 2025 overdue | B-cell non-Hodgkin lymphoma | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07032324 | Jul → Dec 2025 overdue | B-cell non-Hodgkin lymphoma | Qian Wenbin | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06822881 | Feb 2025 → Dec 2026 expected | systemic lupus erythematosus, systemic sclerosis | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06822868 | Feb → Sep 2025 overdue | B-cell non-Hodgkin lymphoma | Kai Hu | Recruiting | No outcome recorded |
| Phase 1 | NCT06734871 | Dec 2024 → Oct 2025 overdue | B-cell non-Hodgkin lymphoma | Aibin Liang，MD，Ph.D. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-08-07 | CARsgen Therapeutics Co., Ltd. | Regulatory CARsgen’s CT1190B Received IND Clearance from the NMPA for the Treatment of Patients with Relapsed/Refractory Large B-Cell Lymphoma carsgen.com ↗ |
| 2026-05-21 | CARsgen Therapeutics Co., Ltd. | Regulatory IND Application for CARsgen’s Allogeneic CD19/CD20 CAR-T CT1190B Accepted carsgen.com ↗ |
| 2025-11-03 | CARsgen Therapeutics Co., Ltd. | Results CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B carsgen.com ↗
The data showed that both allogeneic CAR-T products demonstrated initially favorable safety profiles and encouraging efficacy signals. |
| 2025-09-12 | CARsgen Therapeutics Co., Ltd. | Results Preliminary Clinical Data of Allogeneic CD19/CD20 CAR-T Product for Mantle Cell Lymphoma Reported at Academic Conference carsgen.com ↗
After CT1190B infusion, both patients experienced short-term cytopenia and cytokine release syndrome (CRS), which improved with supportive care. |
All press releases naming this drug 8 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT1190B | “A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell Therapy, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma” NCT07032324 ↗5“A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell Therapy, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma” NCT06822868 ↗ “A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell Therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma” NCT06734871 ↗ “A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell Therapy, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma” NCT07053670 ↗ “CT1190B CAR-T Cell Therapy” NCT06822881 ↗ |
| Modality | Cell therapy | “CT1190B CAR-T Cell Therapy” NCT06734871 ↗ |